Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-020-2715-9 http://scihub22266oqcxt.onion/10.1038/s41586-020-2715-9 32894860!7656507!32894860     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2020 ; 587 (7834): 377-386 Nephropedia Template TP {{tp|p=32894860|t=2020. LifeTime and improving European healthcare through cell-based interceptive medicine |pdf=|usr=}}{{32894860}} gab.com Text LifeTime and improving European healthcare through cell-based interceptive medicine JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=32894860 #FOAvip Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade. Twit Text FOAVip LifeTime and improving European healthcare through cell-based interceptive medicine ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=32894860 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32894860 #FOAvip English Wikipedia <ref>{{Cite pmid|32894860}}</ref> LifeTime and improving European healthcare through cell-based interceptive medicine #MMPMID32894860 Rajewsky N; Almouzni G; Gorski SA; Aerts S; Amit I; Bertero MG; Bock C; Bredenoord AL; Cavalli G; Chiocca S; Clevers H; De Strooper B; Eggert A; Ellenberg J; Fernandez XM; Figlerowicz M; Gasser SM; Hubner N; Kjems J; Knoblich JA; Krabbe G; Lichter P; Linnarsson S; Marine JC; Marioni JC; Marti-Renom MA; Netea MG; Nickel D; Nollmann M; Novak HR; Parkinson H; Piccolo S; Pinheiro I; Pombo A; Popp C; Reik W; Roman-Roman S; Rosenstiel P; Schultze JL; Stegle O; Tanay A; Testa G; Thanos D; Theis FJ; Torres-Padilla ME; Valencia A; Vallot C; van Oudenaarden A; Vidal M; Voet T Nature 2020[Nov]; 587 (7834): 377-386 PMID32894860show ga Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade. |*Cell- and Tissue-Based Therapy[MESH] |*Pathology[MESH] |*Single-Cell Analysis[MESH] |Artificial Intelligence[MESH] |Delivery of Health Care/ethics/*methods/standards/*trends[MESH] |Early Diagnosis[MESH] |Education, Medical[MESH] |Europe[MESH] |Female[MESH] |Health[MESH] |Humans[MESH] |Legislation, Medical[MESH] |Male[MESH]LifeTime and improving European healthcare through cell-based intercep(epmc).pdf DeepDyve Pubget Overpricing